An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...
IEEE Spectrum on MSN
At-home brain stimulation for depression is just the start
Flow’s headset is the first tDCS device approved by the FDA ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
Matter Neuroscience announces collaboration with Stanford Medicine combining Matter protocol with real-time fMRI neurofeedback to support emotion-based interventions in depression Provided by PR ...
Almost half of people with depression meet criteria for being ‘treatment-resistant’, found a new study published in the British Journal of Psychiatry. Definitions for treatment-resistant depression ...
On Tuesday, Alto Neuroscience, Inc. (NYSE:ANRO) revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo. The ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...
Practical guidance for rebuilding strength and reclaiming hope HOUSTON, TX / ACCESS Newswire / February 6, 2026 / ...
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting – Successful outcome from recent FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results